MetaCap

Daxor Corporation (DXR)

NASDAQ: DXRHealth CareMedical/Dental InstrumentsUSD

7.45-0.5891 (-7.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DXR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$43.49M
Ex-dividend date
Jan 5, 2018
52-week range
6.94 – 14.76
Day range
7.00 – 7.88
Volume / Avg
33.83K / 22.43K
Beta
—

52-week range

$6.94$14.76

DXR stock today

Daxor (DXR) closed at $7.45 on Nov 20, down 7.33% (-$0.5891), versus the S&P 500's 3.70% decline. At this level, DXR sits near the bottom of its 52-week range of $6.94 to $14.76: 49.5% below the high, set on Dec 29, 2025 and 7.3% above the low. DXR is down 49.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 43.5%.

Daxor trades at 6.8x its trailing twelve-month earnings per share of $1.10.

Summary generated from market data by MetaCap's automated system. Methodology

About Daxor

Company profile

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.

Industry
Medical/Dental Instruments
CEO
Mr. Michael Richard Feldschuh
Headquarters
Oak Ridge, TN
Website
daxor.com

Financial highlights

Full financials

In fiscal 2011, Daxor generated $1.4 million in revenue, down 8.4% from fiscal 2010, the first decline in the 2 years shown. Daxor reported a net loss of $7.2 million, compared with net income of $5.0 million a year earlier. Gross margin was 54.9% (up from 53.9%) and operating margin -400.1%.

Daxor annual revenue, net income and EPS
Fiscal yearFY 2011FY 2010
Revenue$1.45M$1.58M
Growth-8.42%—
Net income$-7.19M$4.97M
EPS (diluted)$-1.70$1.17

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$20.00+168.46%

  • Strong buy 1
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $18.00High $22.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Q3 2011)
Nov 14, 2011
EPS actual vs est.
$-0.99 vs —

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$0.03
Ex-dividend date
Jan 5, 2018

DXR news

All DXR news

Daxor peers

Health Care sector
DXR peer companies
CompanyPrice% ChgMarket capCompare
MBOTMicrobot Medical Inc.0.68-8.52%$45.67Mvs DXR
SRTSSensus Healthcare Inc.2.26-4.24%$37.20Mvs DXR
MDAISpectral AI Inc. Class A1.04-20.61%$33.47Mvs DXR
LNSRLENSAR Inc.4.46-3.88%$54.83Mvs DXR
TELATELA Bio Inc.0.6885-5.27%$31.11Mvs DXR
XTNTXtant Medical Holdings Inc.0.21-2.82%$29.49Mvs DXR
NSPRInspireMD Inc.0.54-12.97%$29.23Mvs DXR
NEPHNephros Inc.2.61-8.10%$28.37Mvs DXR

Indexes, lists and sector

Daxor stock FAQ

What is Daxor's stock price today?

DXR last traded at $7.45 as of Nov 20, 4:00 PM EST, down 7.33% on the day. Prices are delayed at least 15 minutes.

Does Daxor pay a dividend?

Yes. Daxor pays $0.00 per share annually. The most recent dividend of $0.03 had an ex-dividend date of Jan 5, 2018.

What is DXR's P/E ratio?

DXR trades at a trailing P/E ratio of 6.77.

Who is Daxor's CEO?

Mr. Michael Richard Feldschuh is the chief executive officer of Daxor Corporation.

What is the DXR 52-week high?

The 52-week high for DXR is $14.76 and the 52-week low is $6.94. The stock is currently 49.5% below its high.

Compare DXR